{"id":"NCT04314362","sponsor":"Azura Ophthalmics","briefTitle":"Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)","officialTitle":"A Single-center, Vehicle-controlled, Study to Evaluate Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-07-14","primaryCompletion":"2021-01-06","completion":"2021-01-06","firstPosted":"2020-03-19","resultsPosted":"2023-01-25","lastUpdate":"2023-01-25"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Meibomian Gland Dysfunction"],"interventions":[{"type":"DRUG","name":"AZR-MD-001 ointment/semi-solid drug","otherNames":[]}],"arms":[{"label":"AZR-MD-001 Active","type":"EXPERIMENTAL"},{"label":"AZR-MD-001 Active + Conventional Treatment","type":"EXPERIMENTAL"},{"label":"AZR-MD-001 vehicle","type":"EXPERIMENTAL"}],"summary":"Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.","primaryOutcome":{"measure":"Primary Efficacy for MGD: Change From Baseline to Month 3 in Meibomian Gland Secretion Score (MGS)","timeFrame":"Month 3","effectByArm":[{"arm":"AZR-MD-001 Active","deltaMin":12.8,"sd":11.3},{"arm":"AZR-MD-001 Vehicle","deltaMin":8.8,"sd":5.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Australia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Eye Pain","Eye Irritation","Ocular Discomfort"]}}